CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor
Article in Scientific Reports (September 2023)
The most recent citing publications are shown below. View all 195 publications that cite this research output on Dimensions.
Article in Scientific Reports (September 2023)
Preprint in Research Square (June 2023)
Article in Journal of Medicinal Chemistry (February 2022)